Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Convertible Debt (2020)

Historic Convertible Debt for Barinthus Biotherapeutics (BRNS) over the last 1 years, with Q4 2020 value amounting to $44.7 million.

  • Barinthus Biotherapeutics' Convertible Debt changed N/A to $44.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $44.7 million, marking a year-over-year change of. This contributed to the annual value of $44.7 million for FY2020, which is N/A changed from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Convertible Debt of $44.7 million as of Q4 2020.
  • Barinthus Biotherapeutics' 5-year Convertible Debt high stood at $44.7 million for Q4 2020, and its period low was $44.7 million during Q4 2020.